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Abstract
Background: About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with
endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However,
acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms.
Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients.
Here we test whether tumor hypoxia might commonly produce ER-α loss.
Methods: Using standard molecular and cellular biological assays and a work station/incubator with controllable
oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of
independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic
backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown
and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the
hypoxia-induced decrease in ER-α abundance.
Results: We present the first comprehensive overview of the effects of bona fide low environmental oxygen
(hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α
induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which
involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed
transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite
their varying genomic backgrounds.
Conclusions: These studies reveal a common hypoxia response that produces reduced ER-α expression and cell
cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or
the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine
therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors
may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating
cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to
proliferation via other signaling pathways.
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Background
Breast tumors are classified into subtypes based on mo-
lecular and pathological characteristics that impart prog-
nostic value or determine therapeutic treatment plans.
The most common and clinically relevant feature is
expression of the estrogen receptor alpha (ER-α; ESR1)
transcription factor, which occurs in 70–80% of all
breast tumors. ER-α is activated by the endogenous
hormone 17-beta-estradiol (estrogen), to bind estrogen-
responsive elements (ERE) in DNA and induce gene
transcription (reviewed in [1, 2]). ER-α can also function
as a non-DNA-binding element of other transcription
complexes; and cytosolic, non-genomic functions are
ascribed to specific ER-α splice variants.
Estrogen responsive genes include those required for
survival and proliferation, and most ER-α -positive
breast tumors are dependent on estrogen for growth. As
such, several targeted therapies have been developed that
either compete for estrogen binding (for example tam-
oxifen), or inhibit the body’s ability to produce estrogen
(for example aromatase inhibitors). Most ER-α positive
tumors initially respond well to these therapeutics, and
ER-α expression generally imparts a better 5 year prog-
nosis. However around 30% of ER-α positive tumors are
intrinsically resistant to endocrine therapies and 30–40%
of those that initially responded will become therapy
resistant (reviewed in [1, 2]). Of these, about 20% will
lose ER-α expression. Patients with endocrine-resistant
tumors account for nearly 11,000 annual US breast
cancer deaths.
Heterogeneity of ER-α positive tumors influences
therapeutic responses
As a class, ER-α positive tumors are heterogeneous in
the expression of hundreds of other molecules that may
influence proliferation and survival. For example, some
ER-α positive tumors express activated oncogenes such
as the HER2 receptor tyrosine kinase, or a mutant, acti-
vated phosphoinositide-3-kinase alpha catalytic subunit
(PI3KCA; [3–5]). Other ER-α positive tumors may have
inactivated tumor suppressors such as tumor protein TP53)
and/or retinoblastoma (Rb). Differences may be so pro-
found that ER-α positive tumors are found in both the lu-
minal A and luminal B molecular subsets of breast tumors.
As expected from this heterogeneity, ER-α positive tumors
differ in drug responses and clinical outcomes [6, 7].
Individual ER-α positive breast tumors also exhibit sig-
nificant intra-tumor heterogeneity. Tumors are consid-
ered ER-α positive by clinical histopathological standards
if as few as 1% of cells stain for ER-α expression [8]. The
presence of accompanying ER-α negative cells has been
attributed to factors including genomic instability, epi-
genetic regulation, poorly-defined micro-environmental
conditions, and the ongoing growth and differentiation
of tumor cells from primitive, stem-cell like progenitors
within the tumor mass [9]. As the use of specifically-
targeted therapeutics increases, intra-tumor heterogen-
eity becomes an increasingly important factor in treatment
efficacy [10]. The widespread use of hormone targeted
therapeutics and prevalence of resistance, makes under-
standing the intra- and inter-tumor heterogeneity of ER-α
positive tumor responses of paramount clinical import-
ance. Thus, experimental analysis of only one or a few ER-
α positive cell lines in preclinical studies cannot accurately
reveal the diversity of potential responses among this class
of tumors, nor predict the prevalence of various thera-
peutic responses.
HIF-1α is a key regulator of adaptation to hypoxic
conditions
Conditions of low oxygen (i.e. hypoxia) are hallmarks of
solid tumors, and cells undergo profound alterations to sur-
vive this environment (reviewed in [11]). Hypoxia promotes
the growth of tumors that have reduced apoptotic abilities
[12] increased metastatic potential [13] and increased gen-
omic instability [14–16]. Hypoxia is a poor-prognosis factor
for breast cancer in terms of tumor recurrence, tumor
aggressiveness, disease-free survival and overall survival
[17, 18]. Hypoxic conditions occur in poorly vascularized
regions of rapidly growing tumors, areas located between
70 and 100 μm from blood vessels [19]. Highly transformed
breast cancer cells orchestrate a varety of complex re-
sponses to survive hypoxic conditions, allowing, for ex-
ample, uninterrupted protein synthesis via constitutively
activated mechanistic target of rapamycin (mTOR) signal-
ing [20]. In contrast, non-transformed breast derived cell
lines respond to hypoxia (1% O2) by rapid inhibition of pro-
tein synthesis (reviewed in [21]).
Many features of hypoxic adaptation rely on activation
of the hypoxia inducible factor (HIF) family of transcrip-
tion factors. HIF functions as a heterodimer composed
of an α-subunit (HIF-1α, HIF-2α or HIF-3α) and a β-
subunit (HIF-1β). HIF-1α, and HIF-2α are the main
transcription factors involved in oxygen level sensing
and cell response (reviewed in [11, 16]) while HIF-1β
(ARNT) is constitutively expressed in the nucleus inde-
pendent of oxygen levels. Under normoxic conditions
HIF-1α is hydroxylated on proline 402 and proline 564
by a family of prolyl-4-hydroxylases (PHDs;[22, 23]).
HIF-1α hydroxylation allows recognition by the von
Hippel-Lindau (VHL) tumor suppressor, which targets
HIF-1α to the proteasome for degradation. Under hyp-
oxic conditions HIF-1α degradation is impaired, allowing
nuclear translocation and hetero-dimerization with HIF-
1β on hypoxic-response elements (HRE). HIF-directed
transcription induces genes involved in angiogenesis, gly-
cosylation, tissue remodeling, metabolism, and cell prolif-
eration [24–26]. HIF-1α is an independent predictor of
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poor response to chemo-endocrine therapy, and is nega-
tively associated with disease-free survival in ER-α positive
but not ER-α negative patients [27].
Conflicting observations regarding hypoxic alterations
in ESR1 transcription, ER-α protein stability, and ER-α
transcriptional activity appear in the literature [28–31].
Some of these reports use cell culture with low environ-
mental oxygen, but more often they use treatment with
chemicals that can stabilize HIF-1α to the mimic hyp-
oxic environment. With regard to breast cancer, these
studies also primarily rely on the singular cell line
MCF7, or a cell line of unknown lineage and genomic
content, ZR-75. While this literature generally suggests
that hypoxia promotes decreased ER-α expression, it
does not present a coherent mechanistic picture that
could guide improvements in hormonal therapeutics.
ER-α protein levels are reduced in hypoxic environments
In the current study, we analyze the effect of hypoxia and
HIF expression on ER-α using a panel of ten independently-
derived ER-α positive cell lines. This panel has been previ-
ously characterized by comparative genomic hybridization,
mRNA expression profiling, total genome sequencing,
various high throughput analyses of protein expression and
activation status, and comprehensive drug panel responses
(for example, see [7, 32, 33]). Combined, these cell lines cap-
ture a significant amount of the diverse genetic backgrounds
and accompanying mutations commonly present in ER-α
positive tumors. Cell lines in our study such as BT474
and MDA-MB-361 co-express and constitutively activate
the HER2 receptor tyrosine kinase; five of these cell lines
bear activating mutations in the phosphatidylinositol-4, 5-
bisphosphate 3-kinase subunit PIKC3A; five have mutated
TP53 genes, and lines such as HCC1428 and MDA-MB-
175 maintain wildtype alleles of all of these genes
(Additional file 1; [3–5, 33]). Despite this genomic and
drug response diversity we find that hypoxia commonly
functions through HIF-1α to reduce ER-α protein levels,
impede ER-α directed transcription, and inhibit estrogen-
dependent cell proliferation. The latter occurs even in
cells that co-express receptor tyrosine kinases such as
HER2, which are known to drive breast tumor prolifera-
tion in other settings.
Methods
Cell culture
LY2, MCF7, CAMA-1, MDA-MB-175, MDA-MB-361,
MDA-MB-231 and MDA-MB-435 cell lines were cul-
tured in DMEM. BT474, T47D, ZR75B, MPE600,
HCC1428 cell lines were cultured in RPMI. All cell lines
were obtained as a kind gift from Dr. Joe Gray, (Oregon
Health Sciences University, USA), and maintained with
10% Fetal Bovine Serum (FBS) at 37 °C in 5% CO2 and
21% O2. All cell lines were verified by short tandem
repeat (STR) genotyping. Genomic DNA was extracted
by Wizard SV Genomic DNA purification system
(Promega). STR profiles were compared with publically
available profiles using Promega Powerplex 1.2.
Reagents
Antibodies used in this report are as follows: ER-α
(clone HC-20, Santa Cruz), HIF-1α (BD Bioscience),
HIF-2α (NB100-132, Novus Biologicals), phospho-p70
S6 kinase (p-p70-S6K; 9205, Cell Signaling Technology),
phospho-4E-BP1 (2855, Cell Signaling Technology), β-
Actin (clone AC-15, Sigma-Aldrich), Alexa Fluor- 488
(A-11008, Invitrogen), Alexa Fluor-594 (A11012, Invitro-
gen), HRP-anti-Mouse IgG (NA931V, GE Healthcare),
and HRP-anti-Rabbit IgG (NA934V, GE Healthcare).
Reagents used in this study are estrogen (17-β-estradiol)
used at 10 nM (Sigma-Aldrich), MG132 used at 10 uM
(Cayman Chemical).
Western blot
Western blots were performed as previously [34]. Briefly,
cells were lysed with urea lysis buffer (9 M urea,
150 mM, β-mercaptoethanol and 75 mM Tris pH 7.4),
or RIPA buffer (Cell Signaling #9806), sonicated for 30 s
and centrifuge at 15,00 rpm at 4C for 30 min. Protein
quantification was performed by Bradford (BioRad
Cat.500-0205), and 20–100 μg of protein were loaded in
each well of a polyacrylamide gel. PVDF membranes
were blocked with 5% milk in TBS-T/0.05% (Tris
Buffered Saline with Tween 20 to 0.05%) at room
temperature (RT) for 30 min, primary antibodies were
incubated overnight at 4C in TBS-T/0.05%. After wash-
ing with TBS-T/0.05%, secondary incubation was per-
formed at RT for 45 min followed by TBST/0.05% washes.
Western blot signal was detected using Enhanced Chemi-
luminescent (ECL) substrate (Pierce 32106, or GE Health-
care RPN2235) in a FlourChemE machine. Exposures
were chosen to provide maximum visual information
about the changes in band intensity without causing over-
exposures that would obscure faint signals in neighboring
lanes. Each western blot was repeated from 3 to 6 times,
and the averages and standard deviations for the inten-
sities of the western blot replicates for each figure are
graphed and presented in tabular form in the Additional
files, as indicated throughout the manuscript.
Immune fluorescence
Cells were cultured on glass coverslips in six well plates,
using complete media (RPMI or DMEM) with phenol
red, supplemented with 10% FBS. Hypoxic samples were
placed into the HypOxygen H35 Workstation for 48 h.
Coverslips were washed twice in Phosphate Buffered
Saline (PBS), fixed in Acetone 10 min at -20C, PBS
washed, and nonspecific antibody binding blocked with
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10% Bovine Serum Albumen (BSA) and 5% goat serum.
Antibodies specific for the estrogen receptor alpha chain
(Santa Cruz Biotechnology, HC-20 sc-543) were used at
1:100, anti- rabbit-488 (Molecular Probes/Invitrogen) at
1:1000. Nuclei were counterstained with DAPI (4',6-dia-
midino-2-phenylindole).
Plasmids
Plasmid transfection was performed using Lipofectamine
(Invitrogen) and Plus Reagent (Invitrogen) in Opti-MEM.
ShScramble, shHIF1A and shHIF2A plasmids were previ-
ously described [34], HIF-1αODD was used to produce
stabilize HIF-1α at normoxia [23] pCMV-hER-α was used
to overexpress ER-α [35]. Reporter assays used ALT-4, a
plasmid encoding canonical Estrogen Response DNA
binding sequences (Estrogen Response Elements, ERE)
controlling expression of firefly luciferase [35].
Hypoxia treatment
Cells were subjected to 1% O2 for the specified time
(HypOxygen H35 Workstation). Cells were passaged
under normoxic conditions but cultured and harvested
inside the hypoxia chamber.
ER-α reporter assays and analysis of media estrogenic
effects
To test the estrogenic effects of our normal culture
media, cells were transfected with a plasmid encoding
canonical Estrogen Response DNA binding sequences
(Estrogen Response Elements, ERE) controlling expres-
sion of firefly luciferase [35]. The media we tested in-
cluded: 1) “standard growth media” containing phenol
red, (DMEM for MCF7 or RPMI for BT474, T47D and
ZR75B) with 10% FBS; or 2) “E2 (−), estradiol-free” com-
posed of phenol red-free DMEM with 10% charcoal
stripped FBS; or 3) “E2 (+), defined estrogen media”,
composed of phenol red-free DMEM, 10% charcoal
stripped FBS supplemented with 10 nM estradiol. Cells
incubated with either standard growth media or cells
grown in defined estrogen medium had similarly high
levels of luciferase signal (Additional file 2). Since there
was no difference between the standard media and the
estrogen-defined, phenol red-free media, all experi-
ments, ER-α transcriptional activity assays and prolifera-
tion assays were performed in standard media.
For experiments in Fig. 4, cells were transfected with a
plasmid encoding canonical Estrogen Response DNA
binding sequences (Estrogen Response Elements, ERE)
controlling expression of firefly luciferase [35] and incu-
bated at normoxia or at hypoxia for 48 h.
All luciferase activity was determined by Dual-Glo
Luciferase assay reagent (Promega) measured in a
Monolight 2010 Luminometer (Promega). Firefly lucifer-
ase was normalized to protein concentration.
In vitro growth curves
One hundred thousand cells were plated on 6-well plates
in triplicate. The following day, cells were washed with
PBS, and phenol red free DMEM with 10% charcoal
stripped FBS was added. 10 nM estradiol was added for
E2 (+) media or ethanol carrier for the E2 (−) media.
Every 3 to 4 days, cells were counted.
Cell cycle analysis
Cells were plated into 6-well plates and cultured under
appropriate conditions for 3 days (MCF7, T47D, ZR-75-
B) or 6 days (BT474). Cells were harvested, fixed and
permeabilized in suspension in 70% ethanol, nuclei were
stained with 40 μg/ml propidium iodide and 100 μg/ml
RNAse A. DNA content was analyzed using an Accuri
C6 Fluorescence Activated Cell Sorter (BD Biosciences).
At least 150,000 cells were analyzed per sample. Cell
cycle fractions were determined using the cell cycle
analysis component in the FLOWJO software package
(FLOWJO Enterprise).
Real-time quantitative reverse transcriptase PCR
Total RNA was extracted from cells using RNeasy Mini
Kit (Qiagen) following the manufacturer’s instructions.
cDNA was generated from 1.5 μg of RNA using iScript
(BioRad) following the manufacturer’s instruction. Power
SYBR Green PCR reactions were performed in triplicate
for each sample and analyzed using the AB Step One
Plus sequence detection system. Data were normalized
to TBP levels.
Statistical analysis
Student’s t-test was used to determine significance. All
error bars represent the standard error of the mean.
Two way ANOVA was performed for the growth curve
experiments in Fig. 5 using the Graphpad Software pack-
age. Student’s t-test was also used to analyze whether
our data would reveal enhanced proteolysis of the estro-
gen receptor alpha under hypoxic conditions reported in
Fig. 3d and Additional file 3D . Although we may not
have thoroughly inhibited proteolysis in these experi-
ments, the MCF7 sample showed a statistically clear
increase in protein stability with MG132 treatment in
hypoxic conditions versus normoxic conditions, (signifi-
cance level (alpha) = 0.05, p = 0.044), Additional file 3D.
Data for the other three cell lines did not reach this sig-
nificance, with p values for BT474 of 0.765, for T47D of
0.98, and for ZR-75-B of 0.69.
Results
Hypoxia reduces ER-α protein levels
To more systematically determine the contribution of
hypoxia to ER-α expression and function, we exposed a
diverse set of ER-α positive cell lines to controlled, low
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levels of environmental oxygen (1% O2). The cell lines
are derived from ten independent ER-α positive primary
tumors, providing a diverse representation of tumor ge-
nomes found in ER-α positive breast cancer patients
(Additional file 1); [33]. Protein levels of ER-α were
determined by Western blot after culture at either nor-
moxia or hypoxia (1% O2) for 24 h. All ten tumor cell
lines exhibited a significant reduction in ER-α under this
acute hypoxic condition (Fig. 1a; Additional file 4A;
Additional file 5). To evaluate whether ER-α repression
is transient or persistent, longer hypoxic treatment
(48 h) was analyzed in five of these cell lines (LY2,
MCF7, BT474, T47D and ZR75B). We found that ER-α
protein levels continued to decrease over time in
hypoxia in each cell line (Fig. 1b; Additional file 4B;
Additional file 6). Thus longer hypoxic exposure causes
stronger repression of ER-α, suggesting an important
role of hypoxia in ER-α regulation. In immune-
fluorescence studies, we tested whether the decrease in
ER-α protein occurred in the entire population of cells
or just in a few strongly expressing individual cells. We
assessed ER-α expression after 48 h of culture at 1% oxy-
gen in MCF7, BT474 and T47D. As expected from the
western blot data, the protein level decrease differed for
each cell line. However in each cell line tested, a strong re-





Fig. 1 Hypoxia decreases estrogen receptor-α protein. a Representative western blot of ER-α protein from LY2, MCF7, BT474, T47D, ZR75B, CAMA-
1, MPE600, MDA-MB-175, MDA-MB-361 and HCC1428 cells grown at normoxia (N) or treated with hypoxia (H)(1% O2, 24 h). b Representative
western blot of ER-α protein from LY2, MCF7, BT474, T47D, and ZR75B at 24 or 48 h of hypoxia (1% O2) or normoxia (0 h). β-actin is used as a
loading control. c Immune fluorescence of ER-α (green), DAPI (blue) nuclei, scale bar measures 25 μm. d Western blot of ER-α protein in ZR75B
and T47D cells grown at normoxia (N) or treated with hypoxia (H) (1% O2, 24 h). E2 (+) is phenol red-free DMEM with 10% charcoal stripped FBS
supplemented with 10 nM estradiol and E2 (−) is estrogen-free media (phenol red-free DMEM with 10% charcoal stripped FBS)
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population of cells (Fig. 1c, green). Thus, the hypoxia-
dependent decrease in the level of ER-α occurs in all cells
in a population regardless of basal expression levels.
Estrogen or estrogenic surrogates such a phenol red (a
common constituent of cell culture media) or various
constituents of FBS, have been shown to simultaneously
activate and induce degradation of ER-α (for example:
[36] reviewed in [37]). Since our standard culture media
contains phenol red and FBS and could therefore be
considered to be constitutively activating ER-α, we tested
whether the level of unoccupied ER-α would also be
decreased under hypoxic conditions. We found that cul-
ture in the presence of charcoal-stripped serum and phe-
nol red free media without added estradiol dramatically
increased ER-α levels under normoxia in two representa-
tive cell lines in our collection (Fig. 1d, E2(−) N versus
E2 (+) N lanes; Additional file 4C). However hypoxia
still substantially reduced those ER-α levels in the ab-
sence of estrogen (E2(−) H versus (E2(−) N lanes).
HIF-1α activity reduces expression of ER-α
In view of the predominant role of the HIF family of
transcription factors in the regulation of the hypoxic re-
sponse, we next investigated whether HIF activity regu-
lates ER-α protein levels, and whether a particular
inducible HIF family member could be implicated in the
breast. By western blot, we found that all cell lines in
our panel exhibit a clear induction of HIF-1α under
hypoxic conditions (Fig. 2a; Additional file 7C;
Additional file 8). In contrast, we found that HIF-2α
protein levels were not reliably induced, or in some
cases were decreased by hypoxia (Fig. 2a; lanes N (nor-
moxia) versus H (hypoxia)). These data suggested that if
there was a uniform mechanism which decreased ER-α
protein levels in hypoxia, it was more likely to function
through HIF-1α. This conclusion is consistent with re-
ports that HIF-1α is critical for the metastatic progres-
sion of breast cancer [38] while HIF-2α is expressed in a
tissue restricted fashion that does not include the mam-
mary gland (reviewed in [11]).
To directly investigate the role of HIF-1α in ER-α
regulation, HIF1A was silenced by stably expressed
shRNAs [34] in four genetically diverse ER-positive cell
lines: MCF7, BT474, T47D and ZR75B. Knockdown was
confirmed by qPCR (Fig. 2b, mRNA levels), and HIF-1α
protein levels were determined by western blot (Fig. 2c;
Additional file 7D; Additional file 9). HIF1A mRNA
levels were reduced by about 50% in all cell lines. Silen-
cing HIF1A in these lines partially prevented the hypoxic
reduction in ER-α, implicating HIF-1α as a common
mediator of ER-α modulation (Fig. 2c, H (hypoxic cul-
ture) lanes, shScramble versus shHIF1A). In contrast,
HIF1A knockdown did not affect ER-α protein levels in
normoxic conditions, since HIF-1α is not stable under
normoxia (Fig. 2c, N (normoxic culture), lanes shScramble
versus shHIF1A). In contrast, similar HIF2A knockdown
experiments did not increase ER-α protein levels in either
hypoxic or normoxic conditions (Additional file 7A,
HIF2A mRNA; 7B, ER alpha protein; 7F western blot
quantitation; Additional file 10). Finally, we tested whether
overexpression of an oxygen-insensitive, stable HIF-1α al-
lele (HIF-1αODD, [22]) would decrease ER-α levels in
normoxic conditions, thereby isolating potential other ef-
fects of hypoxia from effects of HIF-1α. In transient trans-
fection studies we found that stable HIF-1α can reduce
ER-α protein levels (Fig. 2d; Additional file 7E; Additional
file 11). Taken together, these findings indicate that HIF-
1α reduces ER-α levels in response to hypoxia in breast
cancer. Our results demonstrate that this is a general
phenomenon, occurring in the context of different breast
tumor genomes.
ER-α is post-transcriptionally regulated by hypoxia
We next investigated whether the decreased ER-α pro-
tein levels observed under hypoxic conditions were a
consequence of reduced ESR1 mRNA abundance, as
seen by some investigators [29, 30] but not by others
[31]. To this end, we compared ESR1 mRNA levels in
our panel of ten ER-positive tumor cell lines following
normoxic or hypoxic treatment (1% O2, 24 h). We found
that mRNA levels of ESR1 were essentially unaffected in
eight of the ten cell lines (Fig. 3a). In the other two lines,
MPE600 and MDA-MB-361, ESR1 message levels
increased 2–3 fold. However, all 10 of these cell lines
exhibited decreased ER-α protein levels in response to
hypoxia. These results indicate that ESR1 is not tran-
scriptionally regulated by HIF-1α activity in any of the
different genetic backgrounds represented by the cells
lines use in our study.
ER-α levels might be decreased under hypoxic condi-
tions if protein synthesis were inhibited, a phenomena
which is reported to occur under anoxic conditions
[39–41] and in non-transformed cells or weakly trans-
formed cells under a variety of less severe O2 tensions
[20]. While this has not been attributed to HIF-1α ac-
tivity, we tested whether protein synthesis was inhibited
in our hypoxic cultures (1% O2), by testing for activat-
ing phosphorylation of two canonical regulators of
protein synthesis: 4E-BP1 (a regulator of cap-dependent
translation initiation), and p70 S6 Kinase (a regulator of
polypeptide initiation and chain elongation). We found
no decrease in activating phosphorylation of either of
these proteins in hypoxic versus normoxic cultures (Fig. 3c
N versus H; Additional file 3C; Additional file 12), indicat-
ing that global protein synthesis is not inhibited in our
hypoxic cultures. In support of these findings, other re-
ports indicate that in contrast to non-transformed cells,
highly transformed breast tumor cell lines such as MCF7
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and BT474 continue mRNA translation under hypoxic
conditions similar to ours (1% O2 [20]. Thus, we conclude
that decreased translation of ESR1 mRNA is not the major
cause of the reduced ER-α protein levels we observed.
We hypothesized that ER-α might be post-
transcriptionally regulated. To test this, we treated
four diverse ER-α -positive breast cancer cell lines
(MCF7, BT474, T47D, and ZR75B) with the prote-
asome inhibitor MG132 (10 μM, 16 h). In each cell
line, culture under hypoxic conditions with MG132
increased ER-α protein levels, despite their varying
genetic backgrounds (Fig. 3d; Additional file 3D). We
tested whether our experiments would reveal that this
represented an increase in proteolysis under hypoxic
versus normoxic conditions. Although we may not have
inhibited proteolysis completely, we found that indeed
MCF7 shows a statistically significant increase in ER-α
protein levels by MG132 treatment in hypoxic condi-
tions (alpha = 0.05, p = 0.044), Additional file 3D,
Additional file 13. Data for the other three cell lines does
not reach this significance, perhaps due to incomplete pro-
teolysis inhibition.
We conclude that proteolysis plays a large role in the
hypoxic regulation of ER-α. Analysis of mRNA levels in
these experiments confirmed that increased levels of ER-
α were not due to increased transcription of ESR1 with
MG132 treatment (Additional file 3A). HIF-1α levels
were also determined as a positive control for MG132





Fig. 2 Hypoxic repression of ER-α is dependent on HIF-1α. a Representative western blots of HIF-1α, HIF-2α and β-actin protein in ten ER-positive
cell lines grown at normoxia or hypoxia (1% O2, 24 h). b qPCR analysis of HIF1A mRNA levels in MCF7, BT474, T47D and ZR75B transfected with
shScramble or shHIF1A. Relative HIF1A mRNA levels normalized to TBP. (Change in HIF1A levels: *p < 0.0001 MCF7, *p = 0.012 BT474, *p < 0.0001
T47D, *p = 0.0046 ZR75B). c Representative western blots of HIF-1α, ER-α and β-actin protein from MCF7, BT474, T47D and ZR75B with either
shScramble or shHIF1A at normoxia and hypoxia (1% O2, 24 h). β-actin is used as a loading control. d Representative western blot of HIF-1α, ER-α
and β-actin protein from MCF7, BT474, T47D and ZR75B with or without the transfection of stabilized HIF-1α (HIF-1αODD)
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We further confirmed the posttranslational regulation
of ER-α by overexpressing ER-α under the control of a
strong hypoxia-insensitive promoter (cytomegalovirus;
CMV; [35]) in the ER-negative cell line MDA-MB-231.
We found that hypoxia (1% O2, 24 h) potently reduced
ER-α protein levels in this line (Fig. 3b; Additional file 3B;
Additional file 15). Furthermore, this experiment uniquely
revealed that the mechanisms regulating ER-α protein
abundance during hypoxia may not be limited to
luminal, ER-α positive subtypes of breast cancer, but
may be more widely activated by hypoxia in very dis-
parate subtypes of breast tumors such as the claudin
low, ER-α negative subtype represented by MDA-MB-
231. We note that the increase in ER-α with MG132
treatment occurred although levels of HIF-1α were also
increased. Taken together, these data suggest that pro-
teasome activity is epistatic to HIF-1α in decreasing




Fig. 3 ER-α is post-transcriptionally regulated by hypoxia. a ESR1 mRNA levels were compared between normoxic conditions (black columns) and
hypoxia treatment (1% O2, 24 h) (gray columns) in a panel of ten ER-positive cell lines (Change in ESR1 mRNA levels: p = 0.56 LY2, p = 0.24 MCF7,
p = 0.48 BT474, p = 0.31 T47D, p = 0.82 ZR75B, p = 0.07 CAMA-1, *p = 0.04 MPE600, p = 0.55 MDA-MB-175, *p = 0.03 MDA-MB-361, p = 0.18
HCC1428). Levels were normalized to TBP. Data are represented as mean ± SEM (from duplicate experiments). b Representative western blot of
MDA-MB-231 wild-type cells at normoxia or MDA-MB-231 overexpressing ER-α at normoxia and hypoxia (1% O2, 24 h) for HIF-1α, ER-α and β-
actin. c Representative western blot of phospho-p70-S6K, phospho-4EBP1 and β-actin protein from MCF7, BT474, T47D, ZR75B at normoxia or
hypoxia (1% O2, 24 h). d Representative western blot of MCF7, BT474, T47D and ZR75B at normoxic or hypoxic conditions (1% O2, 16 h) untreated
or treated with MG132 (10 mM, 16 h) for HIF-1α, ER-α and β-actin
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Hypoxia represses ER-α directed transcription
We hypothesized that reduced levels of ER-α protein
would result in a concomitant decrease in ER-α-directed
transcription. However other reports suggest that hyp-
oxia can induce ligand-independent transcriptional acti-
vation of ER-α [42] or enhance ER-α ligand-dependent
transcription [43]. To rigorously analyze changes in ER-
α activity, we first validated a standard reporter assay
and defined media conditions using cells transfected
with a plasmid encoding firefly luciferase under tran-
scriptional control of an Estrogen Response Element
(ERE) -regulated promoter (Additional file 2; [35]). We
then optimized growth conditions to measure ligand-
dependent induction of the ERE reporter, using phenol-
red free media supplemented with charcoal stripped
serum to remove constitutive estrogenic influences from
our cultures. In MCF7, BT474, T47D and ZR75B trans-
fection experiments we found that the reporter was
correctly silent in the absence of added estradiol, and
correctly induced with the addition of physiological
levels of estradiol under normoxic conditions (Fig. 4a.
Black bars). Culture with estradiol under hypoxic condi-
tions (1% O2, 48 h) revealed a strong and significant re-
duction of ER-α activity relative to normoxic culture
conditions (approximately 2–6 fold; Fig. 4a E2(+), black
versus gray bars) in each cell line tested. Similarly, tran-
scription of the progesterone receptor (PGR), a canonical
estrogen receptor target gene was similarly reduced
(Fig. 4b). Finally, we tested the influence of HIF-1α on
ER-α transcriptional activity by transient overexpression
of a stabilized HIF-1α variant (HIF-1αODD) under nor-
moxic conditions, which also attenuated reporter gene
activity in response to estradiol stimulation (Fig. 4c,
E2(+), grey versus black bars). Taken together, our results
indicate that hypoxic induction of HIF-1α commonly de-
creases the levels of ER-α protein, which in turn reduce
ER-α transcriptional activity in a variety of common
breast tumor genetic backgrounds.
Hypoxia-induced decrease in of ER-α activity inhibits
proliferation
Tumor cells might compensate for loss of ER-α activity
under hypoxic conditions by switching to reliance on an
alternate signaling pathway that could allow continued
proliferation. For example, HER2+/ ER-α positive tumors
represented by cell lines such as BT474 might simply
switch to reliance on HER2 activity in hypoxic environ-
ments. To test the extent to which proliferation was im-
paired by a decrease in ER-α in hypoxic conditions, we
first tested whether our ER-α positive breast cancer cell
lines were dependent on estrogen for growth under
normoxic conditions. As demonstrated by growth curves
assays, estradiol addition to phenol red-free media
containing charcoal stripped serum was required for
substantial growth (Fig. 5c-f, N-E2(+) versus N-E2(−),
black solid versus black dashed lines). This was not true
for exemplar ER-α negative breast cancer cell lines,
which proliferated independent of estrogen addition
(Fig. 5a and b, N-E2(+) versus N-E2(−), black solid ver-
sus black dashed lines). We then compared proliferation
under normoxic versus hypoxic conditions. Interestingly,
the ER-α negative cell lines, MDA-MB-231 and MDA-
MB-453, which are claudin low and luminal B molecular
subtypes respectively, grew identically at 20% or 1% O2
(Fig. 5a and b; Black (normoxic) versus gray (hypoxic)
lines). In contrast, proliferation of ER-α positive cells
was strongly decreased by low oxygen levels despite the
addition of estradiol to the media (Fig. 5c-f; N-E2(+) ver-
sus N-E2(−), black solid versus dashed lines). ER-α posi-
tive cell growth was indistinguishable whether cells were
grown in estrogen-free media under normoxic condi-
tions or estrogen-containing media under hypoxic con-
ditions. To further understand the reduced growth rates
in hypoxic conditions, cell cycle analysis at day 3–6 of
hypoxic versus normoxic culture was performed. We
found that all samples underwent cell cycle arrest: three
of our four exemplar cell lines stall in G1 (BT474, T47D,
ZR75B) in hypoxia, as indicated by an increase in the
percent of cells in G1 versus S and G2/M phases of the
cell cycle (Fig. 5g). The fourth cell line, MCF7, exhibits
S-phase stalling, as demonstrated by the expanded per-
cent of cells in S-phase and smaller G1 and G2/M frac-
tions. In further experiments we found no change in
Annexin V reactivity at day 3 of normoxic versus
hypoxic culture, suggesting little apoptotic induction
(data not shown). These data reveal a strong relationship
between ER-α activity and cell proliferation that is
modulated by hypoxia in a variety of tumor genetic
backgrounds.
Discussion
The recent move towards precision medicine, which aims
to prospectively identify clinical drug responders versus
non-responders, requires a parallel preclinical move to the
experimental use of panels of tumor-derived cell lines to
more accurately assess possible therapeutic responses and
frequencies. Here, we bridge that gap to define the effects
of hypoxia on ER-α expression and activity in a panel of
breast cancer cell lines that represent common genomic
variations seen in human ER-α positive tumors. Previous
work with exemplar cell lines, primarily MCF7 or ZR75,
has suggested a role for hypoxia in reducing ER-α expres-
sion [28, 29, 31, 44]. However the literature taken as a
whole contains multiple, conflicting results particularly
with regard to mechanisms and with no consideration
given to the potential influence of genetic background var-
iations that commonly occur in ER-α positive tumors.
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Thus, common responses that might be relevant for im-
proving hormonal therapies remain unclear.
We surprisingly find that reduced oxygen availability
produces rapid reduction of ER-α protein levels in all of
our genetically-diverse cell lines (Fig. 1a, b). This is largely
effected by enhanced proteolysis, although a theoretical
role for altered ER-α -specific translation attenuation
cannot be entirely ruled out (Fig. 3d, Additional file 3D).
Hypoxia reduces ER-α levels in essentially all of the cells




Fig. 4 Hypoxia represses ER activity. E2 (−) is estrogen-free media (phenol red-free DMEM with 10% charcoal stripped FBS). E2 (+) is phenol red-
free DMEM with 10% charcoal stripped FBS supplemented with 10 nM estradiol. a ER transcriptional activity analyzed at normoxia or at 48 h of
1% O2 using an ERE-directed luciferase reporter construct [35]. (MCF7: *p = 0.043, BT474: *p = 0.004, T47D: *p = 0.032, ZR75B: *p = 0.001). b qPCR
analysis of mRNA levels for endogenous PRG mRNA transcripts at normoxic or hypoxic conditions (1% O2, 24 h). Relative mRNA levels normalized
to TBP. (MCF7: *p = 0.049, BT474: *p = 0.014, T47D: *p = 0.032, ZR75B: *p = 0.047). c ER activity analyzed in control cells or cells transfected with a
stabilized HIF-1α allele (HIF-1αODD) using an ERE-directed luciferase reporter construct [35]. (MCF7: *p = 0.036, BT474: *p = 0.034, T47D: *p < 0.001,
ZR75B: *p = 0.026)





Fig. 5 Hypoxic repression of ER activity inhibits proliferation. In vitro growth curves of cells grown with or without estradiol (E2) and at normoxia
or hypoxia (1% O2). a MDA-MB-231, b MDA-MB-453, c MCF7, d BT474, e T47D and f ZR75B. Dashed lines are estrogen-free media, whereas solid
lines contain 10 nM of estradiol. Black lines represent normoxic conditions, whereas gray lines are cells under hypoxic conditions. Two-way ANOVA
analysis: a p > 0.05 MDA-MB-231, b p > 0.05 MDA-MB-453, c *p < 0.001 MCF7, d *p < 0.001 BT474, e *p < 0.001 T47D, f *p < 0.001 ZR75B. g Comparison
of cell cycle distributions for cultures grown for 3 days at normoxia or hypoxia (1% O2). (T-student test *p < 0.001 MCF7, *p < 0.001 BT474, *p = 0.001
T47D, *p < 0.001 ZR75B). BT474 analysis was at a 6 day time point
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the mechanisms that enhance proteolysis of ER-α during
hypoxia can be activated even in breast tumor derivatives
that are naturally ER-α negative and very distantly related,
for example the claudin low molecular phenotype repre-
sented by MDA-MB-231 (Fig. 3b). Thus, we propose that
the molecular mechanisms that promote ER-α proteolysis
are likely to be fundamental to the hypoxic response, and
that ER-α may be one of a potentially large suite of pro-
teins that undergo proteolytic regulation during hypoxic
adaptation. In support of this hypothesis, others have
shown hypoxia-induced proteolysis of the α-secretases
ADAM10 and TACE without alteration in mRNA levels
in neuroblastoma [45], and of the MYC oncogene in
human colon carcinoma cells and primary human kera-
tinocytes, involving the ubiquitin ligases FBXW7 and
DDB1, and cathepsins D and S [46]. Similarly, the ubi-
quitin ligase Siah2 has been implicated in hypoxic pro-
teolysis of the HIF-1α prolyl hydroxylases PHD1 and
PHD3 [47] and of the E1 subunit of α-ketogluterate
dehydrogenase complex [48].
There is significant controversy regarding hypoxia-
induced alterations in ESR1 mRNA levels. We find that
none of the 10 cell lines in our panel show an obvious
reduction in ESR1 mRNA abundance after 24 h of hyp-
oxic culture, although they exhibit significant, rapid re-
duction in the level of ER-α protein (Fig. 1a versus
Fig. 3a). This concurs with the findings in MCF7 [28]
and ZR75 [31] which assessed mRNA at a similar time
point (24 h). In other reports, a reduction in the level of
ESR1 mRNA involving ERK kinase activity [29] were
determined after 72 h of hypoxic culture, which may
explain their discrepant results. Finally, reports of early
(8–24 h), HIF-1α-dependent decreases in the levels of
ESR1 mRNA [30] in MCF7 and T47D, contrast directly
with our findings. These studies differed in that the level
of ESR1 mRNA was analyzed in estrogen-starved cells in
the presence versus absence of hypoxia. We predict that
our results are most likely to represent the acute, com-
mon behavior of bona fide breast tumors undergoing
hypoxic adaptation in an estrogenic environment such
as the breast or metastatic site in the female body.
Using shRNAs targeting HIF1A and HIF2A we directly
demonstrate that HIF-1α, but not HIF-2α commonly
decreases ER-α protein levels (Fig. 2c versus Additional
file 7B) in hypoxic culture conditions. However, these
shRNA studies only decreased the levels of HIF-1α
mRNA and protein without entirely eliminating expres-
sion, which may explain why ER-α protein levels were
not more robustly restored in hypoxia in these cell lines
(Fig. 2c). Similarly, transient overexpression of a stable
HIF-1α in normoxic conditions did not entirely elimin-
ate ER-α expression (Fig. 2d), which also might be ex-
plained as a technical failure to transfect all cells in the
population. Alternatively, other hypoxia-induced factors
that function independently of HIF-1α expression may
also influence ER-α stability. For example, the weak
HIF-2α expression seen under normoxic conditions
might in fact be stabilizing ER-α in an unknown fashion,
and the reduction in both molecules might be somehow
linked in hypoxia. Proteases activated by hypoxia in
other systems including cathepsins B, D, and S [46, 49]
and calpains [50–52] as well as inducible E3 ubiquitin
ligases such as SIAH2 [48, 53] may also provide HIF-1α
- independent ER-α degradation in hypoxia. However it
is clear from our studies that HIF-1α plays an important
role in ER-α regulation.
Since mRNA levels of ESR1 do not decrease in response
to hypoxia in any of the cell lines we examined (Fig. 3a),
the decreased protein levels cannot result from direct
transcriptional repression by HIF heterodimers or of HIF-
induced transcriptional repressors. Thus HIF activity must
indirectly influence factors that enhance proteolysis of ER-
α. This may simply involve transcriptional induction of
ubiquitin ligases or proteases, or more indirectly by induc-
tion of a known HIF-dependent transcriptional target
such as miRNA-155 [54, 55] or a methyltransferase such
as WDR5 [56]. Alternatively, HIF-1α and ER-α might
compete for transcriptional co-activators, for example
P300/CBP (reviewed in [2]). In this scenario, increased
hypoxic levels of HIF-1α could result in ER-α degradation,
due to the lack of co-activators that prevent proteasome
targeting. Finally, ER-α may compete with HIF-1α for
VHL-mediated ubiquitination and proteasome targeting,
as reported in renal cell carcinomas [57]. Others have im-
plicated HIF-1α in ER-α regulation by overexpression of
chimeric HIF-1α-VP16 [44] and by HIF-1α silencing by
siRNA in a single cell line, MCF7 [30]. However, our re-
sults demonstrate that this activity is more common
among breast tumors than the results in MCF7 would
suggest, and reveal that HIF-1α inhibitors should be fur-
ther explored in preclinical studies as co-therapeutics in
the endocrine therapy setting.
Finally, we find that the hypoxia-induced reduction in
ER-α levels decreases ER-α -directed transcription (Fig. 4a-
d) and significantly reduces proliferation (Fig. 5c-f)
without inducing overt cell death in each cell line tested.
Unexpectedly, this lack of estrogen signaling is not over-
come by switching to other proliferative signaling path-
ways in any of our cells over the time courses we assessed
(Fig. 5, 6–16 days). This leads us to speculate that chronic
residence in hypoxic environments may be one explan-
ation for the later disease reoccurrence seen in some
ER-α positive breast cancer patients. We hypothesize
that a dormant, non-proliferating phenotype may allow
tumor cells to persist undetected, until conditions
change to oxygenate the environment or until cells
eventually switch to proliferation via other signaling
pathways. We note that hypoxia can induce protein
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phosphatase 2A, which preserves viability without pro-
liferation in glioblastoma multiforme-derived cells [58]
and we speculate that a similar mechanism may be at
play in our system. Furthers studies involving chronic
hypoxia are ongoing in our laboratory. The hypoxia
sensitivity of ER-α positive, but not ER-α negative,
basal-like cell lines reported here may also provide one
explanation for clinical observations that ER-α positive
tumors grow more slowly than ER-α negative tumors,
providing patients with better 5 year survival statistics.
We speculate that ER-α negative tumors will grow in
vivo regardless of environmental oxygen levels, whereas
growth of ER-α positive tumors will be limited to that
proportion of the tumor that is oxygenated. Finally, ac-
counting for differential expression of ER-α and other
hypoxia sensitive molecules in hypoxic regions of tu-
mors offers one explanation for the intra-tumor hetero-
geneity of ER-α expression seen in many clinical breast
tumor sections.
Several publications have shown that ER-α levels are re-
duced in regions of potentially hypoxic tissue in human
clinical specimens, although in each case the authors were
unable to determine whether this resulted from a lack of
nutrients, oxygen, or an increase in cellular waste products.
For example, Cooper et al. [28] examined cells adjacent to
necrotic breast tumor cores by immuno-histochemical
methods, and found that ER-α protein levels were de-
creased, HIF-1α levels increased, and expression of the
HIF-1α target gene CA-IX was increased. Similarly,
Kronblad et al. [29] also demonstrated reduced ER-α and
increased HIF-1α halos of tumor cells surrounding nec-
rotic cores. Finally Lloyd, et al. [59] measured the spatial
distribution of ER-α reactivity in relationship to vascularity
in breast tissue sections by immuno-histochemical staining.
Each study found reduced ER-α levels either adjacent to
necrotic cores or distal from vasculature. Unlike clinical re-
sults, we can definitely say that hypoxia alone is enough to
produce reduced ERα protein levels in ER-α positive tumor
cells despite variation in other accompanying genetic
mutations.
Conclusions
This study is the first comprehensive overview of the ef-
fects of low environmental oxygen on ER-α abundance
and transcriptional activity in a diverse set of culture
adapted tumor cell lines independently derived from ER-
α positive breast cancer patients. Our uniform, detailed
analysis of this panel reveals surprising and potentially
actionable homogeneity in the effect of hypoxia on ER-
α. Our findings that there is a common requirement for
the proteasome and HIF-1α in ER-α repression in hyp-
oxic environments, among many different breast cancer
genomes implies that ubiquitin ligase or proteasome in-
hibitors might be widely used in the clinic to potentiate
the effects of hormonal therapies or delay/prevent thera-
peutic resistance. Similarly, the common requirement
for HIF-1α activity implies that specific HIF inhibitors
currently under development may also and perhaps
more specifically improve current endocrine therapies.
Thus this analysis reveals multiple new ideas for badly-
needed improvements in endocrine-based therapeutics.
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Additional file 1: Cell line characteristics. Data assembled from the
citations listed in the table. nd, not determined; wt, wildtype; hom,
homozygous; het, heterozygous; mis, missense; bal, balanced. Numbers
from Neve 2006 represent relative signal intensity on Western blot.
(DOCX 20 kb)
Additional file 2: Standard culture media has estrogenic effects. ER
activity analyzed by a reporter assay at normoxia in estradiol-free media,
E2 (−); standard culture RPMI or DMEM; or defined estrogen media, E2 (+).
(A) MCF7 cell lines and (B) T47D cell lines. See cell culture methods
section for media compositions. (PDF 362 kb)
Additional file 3: (A) qPCR analysis of mRNA levels of ESR1 and HIF1A at
normoxia (N) or hypoxia (H) (1% O2, 24 h) treated with DMSO or MG132.
Relative mRNA levels normalized to TBP. (B-D) Averages and standard
deviations of band intensities calculated for all repeats of each western
blot in Fig. 3. Specific band intensities normalized to the loading control
bands (β-actin). (B) HIF-1α and ER-α protein from Fig. 3b. (C) phospho-
p70-S6K and phospho-4E-BP1 protein from Fig. 3c. (D) HIF-1α and ER-α
protein from Fig. 3d. The ER-α graphs represent ER-α normalized to
compare the increase in ER-α protein levels generated by MG132
treatment in normoxic versus hypoxic conditions. * MCF7 ER-α levels are
significantly different, alpha = 0.05, p = 0.044). (PDF 1787 kb)
Additional file 4: Averages of ER-α band intensities for all repeats of
each western blot in Fig. 1. (A) from all experimental replicates of Fig. 1a.
(B) for Fig. 1b. (C) for Fig. 1d. Specific band intensities normalized to the
loading control bands (β-actin). (PDF 551 kb)
Additional file 5: Averages and standard deviations of ER-α band
intensities calculated for all repeats of each western blot in Fig. 1a.
Specific band intensities normalized to the loading control bands (β-
actin). Calculations derived from at least three independent experiments.
(DOCX 15 kb)
Additional file 6: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 1b. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 15 kb)
Additional file 7: (A) qPCR analysis of mRNA levels for HIF2A in MCF7,
T47D and ZR75B transfected with shScramble (shScr) or shHIF2A. Relative
mRNA levels normalized to TBP. (Change in HIF2A levels: *p = 0.005 MCF7,
*p = 0.019 T47D, *p = 0.012 ZR75B). (B) Representative western blots of
HIF-2α, ER-α and β-actin protein from MCF7, T47D and ZR75B with either
shScramble (shScr) or hHIF2A at normoxia and hypoxia (1% O2, 24 h). β-
actin is used as a loading control. (C-F) Averages and standard deviations
of band intensities calculated for all repeats of each western blot in Fig. 2.
Specific band intensities normalized to the loading control bands (β-
actin). (C) HIF-1α and HIF-2α protein from Fig. 2a. (D) HIF-1α and ER-α
protein from Fig. 2c. (E) HIF-1α and ER-α protein from Fig. 2d. (F) HIF-1α
and ER-α protein from Additional file 7B. (PDF 1953 kb)
Additional file 8: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 2a. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 17 kb)
Additional file 9: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 2c. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 17 kb)
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Additional file 10: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Additional file 7B.
Specific band intensities normalized to the loading control bands (β-
actin). Calculations derived from at least three independent experiments.
(DOCX 16 kb)
Additional file 11: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 2d. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 15 kb)
Additional file 12: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 3c. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 15 kb)
Additional file 13: Normalized western blot values for ER-α protein
levels from blots used to generate Fig. 3d, and the graphs in Additional
file 3D. These values were used to test the relative increase in ER-α levels
induced by MG132 treatment in normoxic versus hypoxic conditions for
statistical significance. (DOCX 15 kb)
Additional file 14: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 3d for HIF-1 alpha.
Specific band intensities normalized to the loading control bands (β-
actin). Calculations derived from at least three independent experiments.
(DOCX 15 kb)
Additional file 15: Averages and standard deviations of band intensities
calculated for all repeats of each western blot in Fig. 3b. Specific band
intensities normalized to the loading control bands (β-actin). Calculations
derived from at least three independent experiments. (DOCX 15 kb)
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